How to validate drug positioning and launches without depending on physician research

Validating positioning, testing the commercial name of a new drug, or preparing MSL materials requires access to medical specialists — a process that costs between R$300 and R$800 per interview, takes 4 to 8 weeks, and still faces regulatory restrictions.

Pharmaceutical synthetic personas solve the three blockers at the same time: they are computational representations of prescribers and patients generated by AI from real previous research data, delivering the same type of insight in 48 hours.

In short, pharmaceutical companies that use synthetic personas reduce cost per respondent by up to 93% and compress the validation cycle from 4 to 8 weeks to 48 hours, while maintaining regulatory compliance with LGPD and CFM requirements.

Why HCP research blocks the launch pipeline — and what to do before that happens

Why is pharmaceutical market research more expensive and slower than in other sectors?

Because the target audience — specialist physicians and patients in therapeutic niches — is hard to recruit, expensive to access (R$300 to R$800 per interview), and surrounded by CFM and LGPD regulatory restrictions that make every stage more complex.

The four reasons HCP research blocks or increases the cost of every pharmaceutical launch

Blocker 1: Specialized audience recruitment

Recruiting 20 cardiologists or 30 patients with a rare disease for a focus group can take 3 to 6 weeks, requires specialized intermediaries, and often results in samples smaller than planned because availability is limited.

Blocker 2: Cost per specialized respondent

An in-depth interview with a medical specialist costs between R$300 and R$800, depending on specialty and region. A focus group with eight physicians can cost from R$6,000 to R$15,000, plus moderation, infrastructure, and analysis costs.

Blocker 3: Regulatory restrictions on HCP interaction

The Federal Council of Medicine has guidelines for the relationship between the pharmaceutical industry and physicians. LGPD adds requirements for collecting and processing personal data from health professionals. Research involving real HCPs requires additional governance.

Blocker 4: Research arrives after the decision and budget are already committed

The regulatory approval process for a drug has fixed dates. Positioning, commercial-name decisions, and sales-force briefings need to happen before those dates. Research that takes 10 weeks does not serve a decision window that closes in three.

In practice: the Head of Marketing decides the positioning by instinct, presents it to the board, commits launch budget, and only weeks later discovers whether the choice was right. Delaying launch to wait for the data means losing market timing.

How synthetic personas solve each of these blockers

How can AI be used for pharmaceutical market research?

By creating synthetic personas of prescribing physicians and patients from real previous research data. These personas answer questions about positioning, name, price, and message in 48 hours, without recruiting real HCPs, without direct interaction, and with lower privacy exposure.

The shift is methodological, but the consequence is business-critical: the Head of Marketing stops waiting weeks for data to validate what has already been decided, and starts having data before deciding. It is the difference between arriving at the board with instinct and arriving with evidence.

Synthetic personas start from existing data. The pharmaceutical company uses previous HCP research, CRM data from medical visits, advisory-board results, or any other information base about prescribers and patients. From that base, Galaxies generates representative profiles.

From there:

• Recruitment: zero. Personas are available 24 hours a day, 7 days a week.

• Cost per respondent: up to 93% lower than interviews with real HCPs.

• Regulatory restrictions: eliminated in the output. Synthetic personas are not real HCPs.

• Timeline: validation in 48 hours instead of 4 to 8 weeks.

Estimated cost by project scope

Reference: the Bradesco Seguros case reported a 93% reduction in cost per respondent in a project using Galaxies synthetic personas.

Six practical applications in the pharmaceutical pipeline

At which stages of the pharmaceutical pipeline are Synthetic Personas most useful?

At six points: commercial-name and positioning testing before approval; validation of MSL materials; willingness-to-pay research; patient-journey mapping; DTC campaign testing; and behavioral segmentation of prescribers.

1. Commercial-name and positioning testing: before regulatory approval, validate how the name and positioning are perceived by prescribers and patients.

2. MSL material validation: test clarity, credibility, and adequacy with synthetic medical profiles.

3. Willingness-to-pay research: estimate price sensitivity and access barriers by therapeutic profile.

4. Patient-journey mapping: understand friction points from diagnosis to treatment adherence.

5. DTC campaign testing: evaluate message understanding and objections before media investment.

6. Prescriber behavioral segmentation: identify early adopters, conservative profiles, and cost-effectiveness-oriented prescribers.

Compliance with LGPD and sector regulations

Are synthetic personas compliant with pharmaceutical-sector regulations and LGPD?

Yes. LGPD defines personal data as information related to an identified or identifiable natural person. Synthetic personas do not satisfy this criterion: no real person can be identified from the synthetic output.

Technical basis: synthetic personas are statistical representations of groups, not records of real individuals.

Legal basis: LGPD defines personal data as “information related to an identified or identifiable natural person.” Synthetic personas do not meet this criterion because no specific person can be identified from the generated profile.

Input data (real research from the laboratory) remain subject to LGPD and must be processed under an appropriate legal basis. The synthetic output — the personas — is outside the regulatory scope when it does not identify real individuals.

Frequently asked questions

How do synthetic personas work in the pharmaceutical sector?

Personas of prescribing physicians, pharmacists, and patients are created from real research data with HCPs and patients, then expanded by AI. They allow teams to test positioning, messages, and MSL materials in 48 hours without recruiting real HCPs or violating regulatory restrictions on interaction with healthcare professionals.

What is the cost of HCP research using synthetic personas?

Cost per synthetic respondent can be up to 93% lower than traditional interviews with medical specialists. While an HCP interview can cost R$300 to R$800, synthetic personas of the same profile deliver insights for a fraction of that value, with validation in 48 hours.

Are synthetic personas compliant with pharmaceutical-sector regulations?

Yes. The Galaxies methodology uses anonymized data and statistical group representations. There is no collection or processing of personal data from physicians or patients in the synthetic output, eliminating the regulatory restrictions of traditional direct-contact research.

At which stage of the pharmaceutical pipeline are synthetic personas most useful?

At any stage that requires validation with prescribers or patients: pre-launch, MSL materials, willingness to pay, patient journey, DTC campaigns, and behavioral segmentation of prescribers.

Do synthetic personas completely replace research with real HCPs?

No. They complement HCP research by amplifying existing data and accelerating rapid validation of messages, positioning, and materials. Clinical studies, strategic advisory boards, and efficacy validations still require real professionals.

Do synthetic personas work for rare diseases and niche specialties?

Yes. For specialties where recruiting real HCPs is difficult or nearly impossible, such as pediatric oncology, rare diseases, and high-complexity neurology, synthetic personas enable validations that otherwise might not happen because of time, cost, or sample availability limitations.

Is it possible to segment synthetic personas by behavioral profile?

Yes. The Galaxies methodology segments prescribers by behavioral profile — early adopters, conservative physicians, cost-effectiveness-oriented profiles — in addition to traditional segmentation by specialty. This granularity directly guides sales-force approach strategy.

How should synthetic-persona results be presented to a pharmaceutical CFO and board?

For the CFO: a real HCP interview costs R$300 to R$800; synthetic personas cost up to 93% less and deliver in 48 hours. For the board: every launch with unvalidated positioning carries repositioning costs that can exceed the validation investment many times over.

Pharmaceutical research does not need to be slow and expensive

For the Head of Marketing at a pharmaceutical company who needs to defend every launch decision to the board without the cost and timeline of traditional HCP research, synthetic personas are the process change that makes validation viable in time for the decision.